國華(00370.HK)擬“2供1”供股 籌資最多約1.02億港元
格隆匯5月11日丨國華(00370.HK)公吿,公司建議按於記錄日期每持有2股現有股份獲發1股供股股份基準,以認購價每股供股股份0.2港元實行供股,透過向合資格股東發行最多508,428,313股供股股份(假設已發行股份數目於記錄日期或前並無變動),以籌集最多約1.017億港元。供股不獲包銷,且將不會提呈予不合資格股東(如有)。
供股(倘獲悉數認購)估計所得款項淨額最多約為9610萬港元(假設已發行股份數目於記錄日期或前並無變動)。待供股條件獲達成後,供股將按非包銷基準進行,而不論暫定配發供股股份接納程度為何。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.